Sahm Adrangi of Kerrisdale Capital Management presented his in-depth investment thesis on Charles River Laboratories (US: CRL) at Best Ideas 2020. Jordon Giancoli joined Sahm for this session.
Charles River Laboratories is the dominant pre-clinical research services outsourcer, with almost 20% market share in a $15bn+ end-market growing in the high-single digits. Charles River’s animal testing models, toxicity testing, and pharmacokinetics — techniques required by the FDA and global regulatory agencies before a drug can proceed to human trial — were used in 85% of the drugs approved last year. CRL’s closest pre-clinical peer, Covance/LabCorp, has just 7% preclinical share with no other domestic competitor above 5% share, making CRL the clear choice for full-suite preclinical projects.
Several recent initiatives should supercharge earnings in 2020 and 2021: 1) cross-selling discovery services to a large list of safety clients (just 1 in 5 safety clients use CRL for discovery today); 2) ability to layer on emerging growth opportunities, like the December 2019 acquisition of a cell therapy asset growing at 30%/year (HemaCare); 3) commitment to surpass 20% Adjusted EBIT margins by the end of 2020 (vs. 18.8% in 2019E); and 4) a supportive industry backdrop. Biopharma R&D spend should grow 10% in 2020, with even faster growth in the early-stage animal trials where CRL makes its living.
Assuming CRL reaches its target margin in 2021 and adds another $600m of acquisitions (consistent with management targets), Sahm thinks CRL can earn over $9/share in 2021. Well-owned clinical-stage CROs like IQV and ICLR trade for 22-24x forward earnings, and CRL has historically traded at a 2-5x premium to the S&P 500. Using Kerrisdale’s $9 earnings estimate and a 22x 2021E P/E, Sahm thinks CRL shares can approach $200/share by the end of the year.
The full session is available exclusively to members of MOI Global.
Members, log in below to access the full session.
Not a member?
Thank you for your interest. Please note that MOI Global is closed to new members at this time. If you would like to join the waiting list, complete the following form:
About the instructor:
Sahm Adrangi is the chief investment officer of Kerrisdale Capital Management, a private investment manager that focuses on value and special situations investments. Prior to founding Kerrisdale Capital Management, Sahm was an investment analyst at Longacre Fund Management, a distressed debt credit fund. Prior to Longacre, Sahm worked in the bankruptcy restructuring group at Chanin Capital Partners and the leveraged finance group of Deutsche Bank Securities. Sahm holds a Bachelor of Arts in Economics from Yale University.